Beverly Hills, California, United States
Fatih M. Uckun, M.D., Ph.D, is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations, including ASCO, ASH and AACR. Dr. Uckun is a Principal Member of the Turkish Academy of Sciences/TUBA (a Member of the European Federation of Academies of Sciences and Humanities/ALLEA and Association of Academies and Societies of Sciences in Asia/AASSA). He earned his doctoral degrees at University of Heidelberg in Germany and completed his residency training in Pediatrics, fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology at the University of Minnesota in the US. Dr. Uckun has more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals in oncology/immuno-oncology as well as infectious diseases and immunology. Dr. Uckun worked 11 years as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy. He worked 6 years as a Professor and Head of Translational Research in Leukemia and Lymphoma of the CCBD and a Principal Investigator of the Stem Cell-Regenerative Medicine Initiative at the at the University of Southern California. He has held executive positions in multiple biotechnology companies and has extensive regulatory experience. He has published more than 500 peer-reviewed papers and he has authored numerous review articles and book chapters. He received numerous awards including the Stohlman Memorial Award of the Leukemia Society of America (now known as the Leukemia and Lymphoma Society/LLS), the highest honor given to a Leukemia Society Scholar. He has served as a member of several editorial boards and NIH grant review/special emphasis panels. In addition, Dr. Uckun has deep knowledge and 20+ years of experience in treatment of infectious diseases and their complications. He served as a Defense Advanced Research Projects Agency (DARPA) PI and directed a universal virus neutralizer program project as part of a countermeasures initiative against viruses that can be used as bioweapons. https://www.researchgate.net/profile/Fatih_Uckun https://loop.frontiersin.org/people/679873/bio https://orcid.org/0000-0001-9334-183X https://sciprofiles.com/profile/fatihuckun
https://www.oncotelic.com/about-us/
As Executive Vice President, Clinical Affairs, Global Head of Clinical and Medical Affairs, and Chief Scientific Officer, Dr. Uckun’s responsibilities include providing medical-scientific leadership and direction for Reven’s pipeline of clinical development programs in sepsis, metabolic disorders, inflammatory disorders, including but not limited to non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NASH), iatrogenic organ toxicity, including chemotherapy-induced liver toxicity, and translational oncology as well as contributing to the strategy, direction and execution of the company's clinical development plans. Dr. Uckun will coordinate collaborations with academic centers and other biotech and pharmaceutical companies and provide day-to-day oversight for internal research, research and development, regulatory, safety as well as clinical operations teams.
As a consultant to the Aptevo leadership, Dr. Uckun provides subject matter expertise in design of patient-centric clinical trials in acute leukemia patients. In collaboration with other leukemia experts at academic health centers in the US and Europe, he contributes to the design of clinical research protocols to evaluate Aptevo's bispecific antibodies as components of innovative multi-modality regimens that may improve the outcome of adult and pediatric acute leukemia patients.